A new study on small-cell lung cancer has revealed a surprising benefit for patients. Although a promising immunotherapy drug did not help people live longer, researchers discovered that patients who received radiation twice daily, rather than once, saw better long-term survival and reported a much higher quality of life.
The research, called NRG-LU005, began by testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy and radiation could help patients live longer. Early results showed no improvement in survival rates with the drug. But when doctors examined the way radiation was given, they noticed a clear positive trend.
A follow-up study in the Journal of Thoracic Oncology examined patients’ emotions during and after treatment. It tracked 544 patients who routinely filled out surveys about their fatigue, physical health, and daily struggles.
As expected, patients saw their quality of life drop sharply during the intense chemoradiation treatments. However, the surveys showed a strong recovery. Just three months after treatment ended, many patients reported feeling better. Between six and 21 months later, a large number said they felt as healthy, or even healthier, than before treatment began.
The biggest difference appeared when comparing the two radiation schedules. Roughly half the patients received standard radiation once a day, while the rest got smaller doses twice a day. Those who had the twice-daily treatments reported a steadier, much better quality of life over time, with far fewer declines than those treated once daily.
Doctors note that because patients were not randomly assigned to different radiation schedules, other health factors may have influenced the results. Those who completed the long-term surveys were generally healthier and had stronger lung function. Even so, the findings offer hope that changing how radiation is given could make recovery easier for people with lung cancer.
